Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 317,211,136
  • Shares Outstanding, K 2,533,028
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • 60-Month Beta 0.38
  • Price/Sales 5.28
  • Price/Cash Flow 41.11
  • Price/Book 8.42
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 23.12% ( +0.33%)
  • Historical Volatility 17.65%
  • IV Percentile 87%
  • IV Rank 68.12%
  • IV High 26.55% on 10/20/23
  • IV Low 15.81% on 02/06/24
  • Put/Call Vol Ratio 0.54
  • Today's Volume 26,292
  • Volume Avg (30-Day) 25,521
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 447,704
  • Open Int (30-Day) 438,849

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 2.01
  • Number of Estimates 8
  • High Estimate 2.25
  • Low Estimate 1.89
  • Prior Year 1.40
  • Growth Rate Est. (year over year) +43.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.38 +4.49%
on 03/20/24
133.10 -5.50%
on 03/27/24
+3.58 (+2.93%)
since 03/19/24
3-Month
117.27 +7.26%
on 01/23/24
133.10 -5.50%
on 03/27/24
+6.89 (+5.80%)
since 01/19/24
52-Week
99.14 +26.87%
on 10/19/23
133.10 -5.50%
on 03/27/24
+11.65 (+10.21%)
since 04/19/23

Most Recent Stories

More News
New Home Sales Due Next Week in Canada

Monday U.S. Featured Earnings Verizon Communications Inc. (NYSE:VZ) (Q1) EPS of $1.12, ...

PSK.TO : 27.73 (+1.28%)
CDNS : 280.25 (-1.98%)
TFC : 36.80 (+3.05%)
TSLA : 147.05 (-1.92%)
V : 269.78 (-0.59%)
META : 481.07 (-4.13%)
TMO : 544.78 (+0.60%)
IBM : 181.58 (+0.06%)
ARE.TO : 17.04 (+0.06%)
MSFT : 399.12 (-1.27%)
AMZN : 174.63 (-2.56%)
MRK : 125.78 (+0.44%)
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...

MRK : 125.78 (+0.44%)
Better Growth Play: Merck or The Vanguard Growth Index Fund?

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

LLY : 726.31 (-2.63%)
PFE : 26.00 (+2.40%)
BMY : 48.93 (+1.30%)
NVO : 122.71 (-0.03%)
GILD : 66.76 (+0.91%)
MRK : 125.78 (+0.44%)
VUG : 322.46 (-2.26%)
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.

Being able to stop a drug's unwanted effects could lead to a larger market share.

MRK : 125.78 (+0.44%)
1 New Green Flag for Moderna and Merck Stock

There's a new reason to believe that their joint projects are going well.

MRNA : 101.41 (-0.58%)
MRK : 125.78 (+0.44%)
2 Dividend Stocks to Buy and Hold Forever

These dividends are about as safe as they come.

JNJ : 147.91 (+1.49%)
MRK : 125.78 (+0.44%)
Down 75%. Is Agenus Stock a Buy on the Dip?

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

RILY : 19.99 (+1.22%)
MRK : 125.78 (+0.44%)
BMY : 48.93 (+1.30%)
GSK : 39.75 (+1.22%)
AGEN : 5.31 (+6.84%)
Forget Shopify: This Stock Has Made Far More Millionaires

It's a reliable winner with plenty more room to run.

MRK : 125.78 (+0.44%)
HYMTF : 52.9950 (+2.31%)
SHOP : 69.67 (+0.23%)
AMZN : 174.63 (-2.56%)
Stocks Tread Water as Investors Brace for U.S. Economic Data

Stocks are flat this morning as market participants digested remarks from a Federal Reserve official and geared up for a flurry of U.S. economic data.

$SPX : 4,967.23 (-0.88%)
SPY : 495.16 (-0.87%)
$DOWI : 37,986.40 (+0.56%)
DIA : 379.80 (+0.57%)
$IUXX : 17,037.65 (-2.05%)
QQQ : 414.65 (-2.07%)
CTAS : 661.29 (-0.17%)
MRK : 125.78 (+0.44%)
NCNO : 29.41 (-1.14%)
GME : 10.42 (+1.07%)
JD-.LN : 116.951 (-2.78%)
SOI.FP : 87.200 (-2.79%)
Stocks Settle Higher on Lower Bond Yields and Quarter-End Window Dressing

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.86%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.39%. Stock indexes...

$SPX : 4,967.23 (-0.88%)
SPY : 495.16 (-0.87%)
$DOWI : 37,986.40 (+0.56%)
DIA : 379.80 (+0.57%)
$IUXX : 17,037.65 (-2.05%)
QQQ : 414.65 (-2.07%)
ZNM24 : 107-290s (+0.19%)
CTAS : 661.29 (-0.17%)
MRK : 125.78 (+0.44%)
MRVL : 62.13 (-4.77%)
EXR : 132.46 (-1.30%)
MDT : 79.48 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 127.53
2nd Resistance Point 126.83
1st Resistance Point 126.30
Last Price 125.78
1st Support Level 125.07
2nd Support Level 124.37
3rd Support Level 123.84

See More

52-Week High 133.10
Last Price 125.78
Fibonacci 61.8% 120.13
Fibonacci 50% 116.12
Fibonacci 38.2% 112.11
52-Week Low 99.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar